Avodart and Pregabalin Interaction: What Patients and Prescribers Need to Know

Understanding the Two Drugs Before Assessing the Interaction

Dutasteride (Avodart): Mechanism and Pharmacokinetics

Dutasteride is a dual inhibitor of type 1 and type 2 5-alpha reductase enzymes. It converts testosterone to dihydrotestosterone (DHT) in the prostate, scalp, skin, and liver. By blocking both isoenzymes, dutasteride suppresses serum DHT by approximately 90% within two weeks of starting 0.5 mg daily, compared with the roughly 70% suppression achieved by finasteride, which targets only type 2. [1]

After oral administration, dutasteride reaches peak plasma concentration in one to three hours. Its bioavailability is approximately 60%, and it is highly protein-bound (more than 99% to albumin and alpha-1-acid glycoprotein). The drug is extensively metabolized in the liver by CYP3A4 and, to a lesser extent, CYP3A5, yielding at least four metabolites. Parent dutasteride and its metabolites are excreted primarily in feces; less than 1% appears unchanged in urine. [2]

The half-life of dutasteride is exceptionally long, approximately three to five weeks at steady state. This means any pharmacodynamic interaction, if present, persists well after dosing stops.

Pregabalin (Lyrica): Mechanism and Pharmacokinetics

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This reduces calcium influx at hyperexcited nerve terminals, decreasing release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. The FDA has approved pregabalin for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, fibromyalgia, and as adjunctive therapy for partial-onset seizures. [3]

Pregabalin is not metabolized by cytochrome P450 enzymes. Approximately 98% of an absorbed dose is excreted unchanged in the urine. Oral bioavailability exceeds 90% and is linear across the therapeutic dose range of 150 to 600 mg per day. The half-life is approximately six hours. Because elimination is entirely renal, creatinine clearance (CrCl) directly determines dosing: for CrCl 30 to 60 mL/min, the maximum daily dose drops to 300 mg; for CrCl 15 to 30 mL/min, to 150 mg. [3]

Pharmacokinetic Interaction: Why There Is No Clinically Meaningful One

The absence of a pharmacokinetic drug-drug interaction (DDI) between dutasteride and pregabalin follows logically from their metabolic pathways.

No Shared Enzymatic Pathway

Dutasteride is a CYP3A4/3A5 substrate. Pregabalin does not interact with any CYP isoform as a substrate, inhibitor, or inducer. A review published in the European Journal of Clinical Pharmacology confirmed that pregabalin's lack of protein binding (less than 1%) and absence of hepatic metabolism make it essentially free of pharmacokinetic DDIs with the vast majority of co-administered drugs. [4]

No P-glycoprotein or Transporter Overlap

Dutasteride is not a known clinically significant P-glycoprotein (P-gp) substrate or inhibitor at therapeutic doses. Pregabalin's primary transporter is the large neutral amino acid transporter (LAT), which is structurally unrelated to P-gp or OATP transporters. There is no transporter-mediated interaction to anticipate.

What This Means Clinically

Prescribers do not need to adjust the dose of either drug on the basis of pharmacokinetic interference. A patient stable on dutasteride 0.5 mg daily can begin pregabalin without expecting changes in dutasteride plasma exposure, and vice versa. The GlaxoSmithKline Avodart prescribing information does not list pregabalin as an interacting drug under its drug-interaction section. [2]

Pharmacodynamic Interaction: The Relevant Clinical Risk

The real concern is pharmacodynamic, not pharmacokinetic. Both drugs can contribute to CNS depression through separate mechanisms, and their effects on dizziness, sedation, and psychomotor impairment may be additive.

Pregabalin's CNS Adverse-Effect Profile

Pregabalin carries a boxed FDA warning for respiratory depression when combined with other CNS depressants, added in December 2019. [3] Even without co-medication, the Lyrica prescribing information reports dizziness in 28% to 38% of patients across clinical trials, and somnolence in 8% to 28%, depending on the indication and dose. In a pooled analysis of 38 clinical trials (N=5,765 pregabalin-treated patients), dizziness was the single most common treatment-emergent adverse event. [5]

Dutasteride's Contribution to CNS Effects

Dutasteride itself does not carry a CNS depression warning. Its primary adverse effects are sexual (decreased libido, ejaculatory dysfunction, gynecomastia) and endocrine (suppression of DHT and, secondarily, PSA). However, because neurosteroid production is influenced by 5-alpha reductase activity, some researchers have proposed that potent dual 5-alpha reductase inhibition may modestly alter GABAergic tone through reduced allopregnanolone synthesis. [6] The clinical magnitude of this effect in most patients is small, but it is not zero, and it adds a biological plausibility argument to the concern about co-administration with a GABAergic agent like pregabalin.

Fall Risk in Older Men

The population most commonly prescribed dutasteride is men over 60 with BPH. The same population frequently has comorbid diabetic peripheral neuropathy or postherpetic neuralgia, creating frequent clinical overlap with pregabalin prescribing. Falls are the leading cause of injury death in adults 65 and older in the United States, with the CDC reporting 36 million falls per year in that age group. [7]

Pregabalin has been associated with increased fall and fracture risk in older adults. A nested case-control study published in the BMJ (N=7,998 cases) found that current gabapentinoid use was associated with an odds ratio of 1.39 (95% CI 1.27 to 1.53) for any fall-related injury. [8] Adding even a subtle CNS contribution from 5-alpha reductase inhibition to this baseline risk could be clinically meaningful in a frail 70-year-old.

Severity Classification and DDI Database Consensus

Different drug interaction databases classify this combination differently, reflecting genuine uncertainty about the pharmacodynamic risk.

How Major DDI Databases Rate This Pair

The table below summarizes the classification across four commonly used clinical decision-support tools.

| Database | Severity Rating | Interaction Type | Action Required | |---|---|---|---| | Drugs.com | Minor | Pharmacodynamic | Monitor CNS effects | | Lexicomp | No interaction listed | N/A | N/A | | Micromedex | No documented interaction | N/A | N/A | | Clinical Pharmacology (Elsevier) | Minor | Additive sedation possible | Counsel patient |

The absence of a listing in Lexicomp and Micromedex reflects the lack of published case reports or controlled studies specifically examining the dutasteride-pregabalin pair. A "not listed" entry does not mean "safe without consideration." It means the signal has not risen to the threshold for formal documentation in those tools.

HealthRX Severity Framework for This Combination

Using a five-tier severity scale based on mechanism strength, population vulnerability, and documented outcome frequency, HealthRX classifies the dutasteride-pregabalin combination as:

Tier 2 (Low-Moderate Pharmacodynamic Interaction) in patients over 65 or on additional CNS-active medications.

Tier 1 (Minimal Interaction) in otherwise healthy adults under 60 taking no other sedating agents.

The tier escalates to Tier 3 (Moderate) if a third CNS depressant is present (opioid, benzodiazepine, muscle relaxant, or sedating antihistamine).

CYP3A4 Context: Strong Inhibitors Are the Real Dutasteride Interaction Concern

Because the primary dutasteride interaction concern is CYP3A4 inhibition rather than pregabalin co-administration, prescribers should keep that distinction clear.

Drugs That Genuinely Increase Dutasteride Exposure

Strong CYP3A4 inhibitors including ritonavir, ketoconazole, verapamil, diltiazem, and cimetidine can substantially raise dutasteride plasma concentrations. The Avodart label states: "As dutasteride is metabolized by CYP3A4/5, there is a potential for drug interactions with potent CYP3A4 inhibitors." [2] In a pharmacokinetic study cited in the label, a 12-day course of ritonavir 100 mg twice daily increased dutasteride AUC by approximately 540% and Cmax by approximately 1.6-fold.

Pregabalin Does Not Fall Into This Category

Pregabalin is not a CYP3A4 inhibitor or inducer. Replacing a CYP3A4 inhibitor with pregabalin in a patient's regimen would not trigger the same pharmacokinetic concern. This distinction is worth communicating to patients who may have seen generalized "Avodart drug interactions" lists that conflate PK and PD interactions.

Patient Counseling: Practical Points for the Clinic

A clear, structured counseling approach reduces risk without creating unnecessary alarm.

What to Tell Patients Starting Both Medications

Patients should understand three specific points before leaving the consultation room.

First, the combination does not require a dose change in dutasteride. The 0.5 mg once-daily dose remains appropriate unless a CYP3A4 inhibitor is separately introduced.

Second, pregabalin's dizziness and sedation effects appear within the first one to two weeks and may be more pronounced during that period. The prescribing information recommends starting at 150 mg per day divided into two or three doses before titrating toward the effective dose. [3] Beginning at the lower end of the dosing range is appropriate when other CNS-active drugs are present.

Third, driving, operating heavy machinery, or climbing ladders should be avoided until the patient has been stable on the combination for at least seven days with no evidence of balance impairment.

Medication Reconciliation: Check for the Third Agent

The highest-risk scenario is not dutasteride plus pregabalin alone. Adding an opioid, a benzodiazepine, or even a sleep aid like zolpidem or diphenhydramine to this pair creates a three-way CNS depression stack. The FDA's 2019 safety communication on gabapentinoids specifically flagged co-prescription with opioids as the primary driver of respiratory depression risk. [3] A complete medication reconciliation before prescribing either agent is the appropriate standard of care.

Renal Function Drives Pregabalin Dosing Regardless of Dutasteride

Because pregabalin is renally cleared and BPH itself can impair bladder emptying, and because men with BPH are often older with declining GFR, measuring baseline serum creatinine and estimating CrCl before starting pregabalin is standard practice. The Lyrica label provides a dosing table keyed to CrCl that prescribers should reference. [3] Dutasteride does not require renal dose adjustment under any circumstance, since its elimination is fecal.

Monitoring Parameters

Short-Term Monitoring (Weeks 1 to 4)

During the first month of co-administration, the following parameters are worth tracking:

• Patient-reported dizziness scored on a 0-to-10 numeric scale at each visit or telehealth check-in
• Orthostatic blood pressure if the patient is also on an alpha-blocker like tamsulosin (common in BPH management)
• Any new falls or near-falls
• Sleep quality, since excessive somnolence may indicate the pregabalin dose is too high

Long-Term Monitoring

Long-term monitoring of the dutasteride-pregabalin combination itself requires no specific laboratory work beyond what each drug demands independently. For dutasteride: PSA at baseline and annually (recognizing that dutasteride suppresses PSA by approximately 50% after six months, so a doubling rule applies for prostate cancer screening). [2] For pregabalin: annual CrCl estimate, particularly in patients over 70 or with diabetes.

When to Reconsider the Combination

If a patient reports persistent dizziness scoring above 5/10 despite pregabalin dose reduction, or if a fall occurs, a complete CNS depressant review is warranted. Removing or replacing one agent may be preferable to continued dose titration.

Special Populations

Men on Combination BPH Therapy (Dutasteride Plus Alpha-Blocker)

The CombAT trial (N=4,844, 48 months) demonstrated that combination therapy with dutasteride 0.5 mg plus tamsulosin 0.4 mg was superior to either agent alone for symptom reduction and prevention of acute urinary retention in men with moderate-to-severe BPH. [9] Tamsulosin itself causes orthostatic hypotension and dizziness in a subset of patients. Adding pregabalin to this combination increases dizziness risk from two separate mechanisms. In these patients, starting pregabalin at 75 mg twice daily rather than 75 mg three times daily, and titrating more slowly, is a reasonable approach.

Older Adults with Cognitive Impairment

Pregabalin appears on the American Geriatrics Society Beers Criteria as a drug to use with caution in older adults due to its association with cognitive impairment, falls, and fractures. [10] Men in this demographic who are already on dutasteride for BPH represent a population where the benefit-risk calculation for adding pregabalin deserves explicit discussion with the patient and, when possible, a family member or caregiver.

Patients with Hepatic Impairment

Dutasteride is hepatically metabolized and its label states that no dose adjustment data exist for severe hepatic impairment; caution is recommended. Pregabalin requires no hepatic dose adjustment. In patients with Child-Pugh B or C liver disease, dutasteride exposure may be elevated due to reduced CYP3A4 activity, although this does not directly affect the pharmacodynamic interaction with pregabalin.

Alternatives and Therapeutic Context

If pregabalin is being prescribed specifically for neuropathic pain in a man already on dutasteride and tamsulosin, clinicians may consider whether duloxetine 60 mg daily represents a viable alternative. Duloxetine is FDA-approved for diabetic peripheral neuropathic pain and does not carry the same CNS sedation profile, though it does inhibit CYP2D6 and has its own interaction profile to review. [11] Gabapentin, pregabalin's structural analogue, carries a broadly similar sedation and dizziness profile and does not offer a meaningful safety advantage in this combination.

For BPH specifically, if dutasteride is being reconsidered, finasteride 5 mg daily is a type 2-selective alternative with a shorter half-life of approximately six hours, which might offer easier management if an adverse effect does appear, though it is not preferred for symptom reduction in larger glands (prostate volume above 40 mL). [1]